Advertisement
UK markets close in 1 hour 46 minutes
  • FTSE 100

    8,075.82
    +31.01 (+0.39%)
     
  • FTSE 250

    19,770.02
    -29.70 (-0.15%)
     
  • AIM

    755.29
    +0.42 (+0.06%)
     
  • GBP/EUR

    1.1639
    +0.0011 (+0.10%)
     
  • GBP/USD

    1.2451
    -0.0002 (-0.01%)
     
  • Bitcoin GBP

    53,180.23
    -216.95 (-0.41%)
     
  • CMC Crypto 200

    1,427.73
    +3.63 (+0.25%)
     
  • S&P 500

    5,087.07
    +16.52 (+0.33%)
     
  • DOW

    38,472.67
    -31.02 (-0.08%)
     
  • CRUDE OIL

    82.89
    -0.47 (-0.56%)
     
  • GOLD FUTURES

    2,335.30
    -6.80 (-0.29%)
     
  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     
  • HANG SENG

    17,201.27
    +372.34 (+2.21%)
     
  • DAX

    18,143.73
    +6.08 (+0.03%)
     
  • CAC 40

    8,129.99
    +24.21 (+0.30%)
     

A Short Guide to the Novartis-AveXis Deal

A Short Guide to the Novartis-AveXis Deal

On May 15, leading pharmaceutical company Novartis (NVS) acquired AveXis, a US-based clinical-stage gene therapy company. This transaction strengthens Novartis’s position as a leader in gene therapy and neuroscience. The chart below summarizes the deal.